Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18Neoplasms 18Breast Neoplasms 16Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 10Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Hematopoietic and Lymphatic System Neoplasm 6Hematologic Neoplasms 6Ovarian Neoplasms 5Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Mouth Neoplasms 3Hematopoietic and Lymphoid System Neoplasm 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Sarcoma 2Radiodermatitis 2Peritoneal Neoplasms 2Pathologic Complete Response 2Parotid Neoplasms 2Motor Activity 2Melanoma 2Malignant Solid Neoplasm 2

Interventions

Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Progressive Metastatic Castrate Resistant Prostate Cancer × Standard of Care × Clear all
NCT07206056 2026-06-03

TulmiSTAR-01

Novartis

Phase 1/2 Recruiting
188 enrolled
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡